Stock Analiz

Trinity Biotech PLC TRIB

Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 1992 · data as of November 13, 2026

$6.10Market cap $5M
Open the interactive analysis →

Trinity Biotech PLC (TRIB) is a healthcare company listed in the US with a market value of about $5M. In fiscal year 2025 it had revenue of $44M and net income of -$37M, a net margin of -85.4%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -7% a year, a 5-year average ROIC of 2%.

About Trinity Biotech

Trinity Biotech is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 1992. Revenue went from $100M in 2015 to $44M in 2025, a decline of about 7.9% a year. It was profitable in 2 of the last 10 years in our data. Its share count fell by 26% over three years (buybacks).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • More cash than debt, or low debt to equity
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.1
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-245.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)8.3%
Revenue growth (5 yrs, per year)-7.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-32.9%
ROIC (5-yr avg.)2.3%
Profitable years (of last 10)2
Years paying a dividend1

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$44M$62M$57M$63M$81M$102M$90M$97M$99M$100M
Net income-$37M-$32M-$24M-$41M$875000-$6M-$29M-$22M-$40M-$101M
Free cash flow-$12M-$5M-$12M-$2M$11M$21M$3M-$299000$4M$6M
EPS (diluted)$-62.43$-39.09$-29.54$-50.43$1.08$-7.86$-35.56$-27.17$-49.52$-123.75
Net margin-85.4%-51.6%-42.3%-65.6%1.1%-6.3%-32.0%-22.8%-40.6%-101.0%
ROIC————4.6%0.1%-26.9%-13.7%-23.1%-18.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Trinity Biotech pay a dividend?

Not currently.

Is Trinity Biotech a good stock to buy?

We do not give buy or sell advice. Trinity Biotech scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.